Hui Shao,
Assistant Professor
Department:
Pharmaceutical Outcomes & Policy
Business Phone:
(352) 294-8323
Business Email:
hui.shao@ufl.edu
Teaching Profile
Courses Taught
2020-2023
PHA5267 Prin Pharm-Economics
2021-2024
PHA6940 Supervised Teaching
2021-2022
PHA6971 Research for Master’s Thesis
2020-2022
PHA6935 Selected Topics in Pharmacy
2020-2023,2025
PHA6910 Supervised Research
2021-2022
PHA6805 Applied Data Interpretation and Reporting of Findings in Pharmacy
2020-2025
PHA7979 Advanced Research
2021-2023
PHA6265 Introduction to Pharmaceutical Outcomes and Policy I
2021-2024
PHA6936 Advanced Topics in Pharmaceutical Sciences
2021-2024
PHA6937 Topics in Pharmaceutical Administration
2020-2021,2025
PHA7980 Research for Doctoral Dissertation
2019
PHA5878C Pt Care 3: Cv and Pulm
2023
PHA6946 Practicum in the Pharmaceutical Sciences
Publications
Academic Articles
2025
Capturing the Additional Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists Beyond the Control of Traditional Risk Factors in People With Diabetes.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[DOI] 10.1016/j.jval.2025.01.015.
[PMID] 39922304.
2025
Developing a Computable Phenotype for Identifying Children, Adolescents, and Young Adults With Diabetes Using Electronic Health Records in the DiCAYA Network
Diabetes Care.
[DOI] 10.2337/dc24-1972.
2025
Developing an automated algorithm for identification of children and adolescents with diabetes using electronic health records from the OneFlorida+ clinical research network
Diabetes, Obesity and Metabolism.
27(1):102-110
[DOI] 10.1111/dom.15987.
[PMID] 39344840.
2025
Incidence and Risk Factors of Diagnosed Young-Adult-Onset Type 2 Diabetes in the U.S.: The National Health Interview Survey 2016–2022
Diabetes Care.
48(3):371-380
[DOI] 10.2337/dc24-1699.
2025
Long‐term health benefit and economic return of time in range (TIR) improvement in individuals with type 2 diabetes
Diabetes, Obesity and Metabolism.
27(3):1564-1571
[DOI] 10.1111/dom.16168.
2025
Value-Based Pricing and Its Implications for the Newly Announced Medicare Negotiated Price Under the Inflation Reduction Act
Diabetes Care.
48(4):e44-e46
[DOI] 10.2337/dc24-2403.
[PMID] 39841556.
2024
5-Year simulation of diabetes-related complications in people treated with tirzepatide or semaglutide versus insulin glargine.
Diabetes, obesity & metabolism.
26(2):463-472
[DOI] 10.1111/dom.15332.
[PMID] 37867175.
2024
Associations Between Postdischarge Care and Cognitive Impairment–Related Hospital Readmissions for Ketoacidosis and Severe Hypoglycemia in Adults With Diabetes
Diabetes Care.
47(2):225-232
[DOI] 10.2337/dca23-0013.
[PMID] 38048487.
2024
Geographic variation and racial disparities in adoption of newer glucose-lowering drugs with cardiovascular benefits among US Medicare beneficiaries with type 2 diabetes.
PloS one.
19(1)
[DOI] 10.1371/journal.pone.0297208.
[PMID] 38285682.
2024
Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in U.S. Older Adults With Type 2 Diabetes : A Target Trial Emulation Study.
Annals of internal medicine.
177(8):1004-1015
[DOI] 10.7326/M24-0329.
[PMID] 39008852.
2024
Incremental burden on health-related quality of life, health service utilization and direct medical expenditures associated with cognitive impairment among non-institutionalized people with diabetes aged 65 years and older.
Diabetes, obesity & metabolism.
26(1):275-282
[DOI] 10.1111/dom.15313.
[PMID] 37789596.
2024
Racial/Ethnic Disparities in Use of Angiotensin II Receptor Type 2/4 Stimulatory Vs. Inhibitory Antihypertensive Among Hypertensive Adults in the USA.
Journal of racial and ethnic health disparities.
[DOI] 10.1007/s40615-024-01970-w.
[PMID] 38498117.
2024
Sodium-glucose cotransporter-2 inhibitors and incidence of atrial fibrillation in older adults with type 2 diabetes: a retrospective cohort analysis.
Frontiers in pharmacology.
15
[DOI] 10.3389/fphar.2024.1379251.
[PMID] 38846094.
2024
Sodium‐glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real‐world patients with type 2 diabetes
Diabetes, Obesity and Metabolism.
26(12):5727-5736
[DOI] 10.1111/dom.15943.
2024
Some patients with type 2 diabetes may benefit from intensive glycaemic and blood pressure control: A post-hoc machine learning analysis of ACCORD trial data.
Diabetes, obesity & metabolism.
26(4):1502-1509
[DOI] 10.1111/dom.15453.
[PMID] 38297986.
2024
Trends in utilization patterns of newer glucose-lowering drugs in US adults with type 2 diabetes and a history of coronary heart disease or heart failure: 2005-2019.
Primary care diabetes.
18(5):561-563
[DOI] 10.1016/j.pcd.2024.07.003.
[PMID] 39095227.
2024
Uncertainty-Aware Pre-Trained Foundation Models for Patient Risk Prediction via Gaussian Process
Companion Proceedings of the ACM Web Conference 2024.
1162-1165
[DOI] 10.1145/3589335.3651456.
[PMID] 40041765.
2023
Association between first-line antidepressant use and risk of dementia in older adults: a retrospective cohort study.
Research square.
[DOI] 10.21203/rs.3.rs-3266805/v1.
[PMID] 37790299.
2023
Association between first-line antidepressant use and risk of dementia in older adults: a retrospective cohort study.
BMC geriatrics.
23(1)
[DOI] 10.1186/s12877-023-04475-z.
[PMID] 38066473.
2023
Changes in racial and ethnic disparities in glucose-lowering drug utilization and glycated haemoglobin A1c in US adults with diabetes: 2005-2018.
Diabetes, obesity & metabolism.
25(2):516-525
[DOI] 10.1111/dom.14894.
[PMID] 36251173.
2023
Cost-effectiveness analysis of monthly, 3-monthly, and 6-monthly long-acting injectable and oral paliperidone in adults with schizophrenia.
Journal of managed care & specialty pharmacy.
29(8):884-895
[DOI] 10.18553/jmcp.2023.29.8.884.
[PMID] 37523313.
2023
Newer glucose-lowering drugs and risk of dementia: A systematic review and meta-analysis of observational studies.
Journal of the American Geriatrics Society.
71(7):2096-2106
[DOI] 10.1111/jgs.18306.
[PMID] 36821780.
2023
The role of health system penetration rate in estimating the prevalence of type 1 diabetes in children and adolescents using electronic health records
Journal of the American Medical Informatics Association.
31(1):165-173
[DOI] 10.1093/jamia/ocad194.
[PMID] 37812771.
2022
A machine learning approach identifies modulators of heart failure hospitalization prevention among patients with type 2 diabetes: A revisit to the ACCORD trial.
Journal of diabetes and its complications.
36(9)
[DOI] 10.1016/j.jdiacomp.2022.108287.
[PMID] 36007486.
2022
A National Catalog of Mapped Short-Form Six-Dimension Utility Scores for Chronic Conditions in the United States From 2010 to 2015.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
25(8):1328-1335
[DOI] 10.1016/j.jval.2022.02.011.
[PMID] 35367137.
2022
Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US.
Diabetes therapy : research, treatment and education of diabetes and related disorders.
13(9):1659-1670
[DOI] 10.1007/s13300-022-01300-5.
[PMID] 35930188.
2022
Economic Evaluation of the $35 Insulin Copay Cap Policy in Medicare and Its Implication for Future Interventions
Diabetes Care.
45(11):e161-e162
[DOI] 10.2337/dc22-1230.
[PMID] 36099174.
2022
Efficacy of iGlarLixi on 5-year risk of diabetes-related complications: A simulation study.
Journal of diabetes and its complications.
36(3)
[DOI] 10.1016/j.jdiacomp.2022.108132.
[PMID] 35101326.
2022
Growing global burden of type 1 diabetes needs multitiered precision public health interventions.
The lancet. Diabetes & endocrinology.
10(10):688-689
[DOI] 10.1016/S2213-8587(22)00257-1.
[PMID] 36113506.
2022
Lowering hemoglobin A1c level to less than 6.0% in people with type 2 diabetes may reduce major adverse cardiovascular events: a Bayesian’s narrative.
Current medical research and opinion.
38(11):1883-1884
[DOI] 10.1080/03007995.2022.2129234.
[PMID] 36164760.
2022
Newer glucose-lowering drugs and risk of dementia: A meta-analysis of cardiovascular outcome trials.
Journal of the American Geriatrics Society.
70(9):2719-2722
[DOI] 10.1111/jgs.17895.
[PMID] 35612586.
2022
Potential Gains in Life Expectancy Associated With Achieving Treatment Goals in US Adults With Type 2 Diabetes.
JAMA network open.
5(4)
[DOI] 10.1001/jamanetworkopen.2022.7705.
[PMID] 35435970.
2022
Projected Impact of the Medicare Part D Senior Savings Model on Diabetes-Related Health and Economic Outcomes Among Insulin Users Covered by Medicare
Diabetes Care.
45(8):1814-1821
[DOI] 10.2337/dc21-2601.
[PMID] 35700384.
2022
Socioeconomic Factors Play a More Important Role than Clinical Needs in the Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in People With Type 2 Diabetes
Diabetes Care.
45(2):e32-e33
[DOI] 10.2337/dc21-1800.
2022
Syndromic Surveillance Systems for Mass Gatherings: A Scoping Review.
International journal of environmental research and public health.
19(8)
[DOI] 10.3390/ijerph19084673.
[PMID] 35457541.
2022
Using modern risk engines and machine learning/artificial intelligence to predict diabetes complications: A focus on the BRAVO model.
Journal of diabetes and its complications.
36(11)
[DOI] 10.1016/j.jdiacomp.2022.108316.
[PMID] 36201893.
2021
A varied approach to left ventricular assist device follow-up improves cost-effectiveness.
Current medical research and opinion.
37(9):1501-1505
[DOI] 10.1080/03007995.2021.1948395.
[PMID] 34181489.
2021
Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A retrospective cohort study.
Journal of diabetes and its complications.
35(9)
[DOI] 10.1016/j.jdiacomp.2021.107972.
[PMID] 34247911.
2021
Comparing the downstream costs and healthcare utilization associated with the use of low-dose computed tomography (LDCT) in lung cancer screening in patients with and without alzheimer’s disease and related dementias (ADRD).
Current medical research and opinion.
37(10):1731-1737
[DOI] 10.1080/03007995.2021.1953972.
[PMID] 34252317.
2021
Cost-Effectiveness of the New 2018 American College of Physicians Glycemic Control Guidance Statements Among US Adults With Type 2 Diabetes.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
24(2):227-235
[DOI] 10.1016/j.jval.2020.09.010.
[PMID] 33518029.
2021
The diminishing cost-effectiveness of the newer glucose-lowering drug classes in the United States: 2010-2018.
Current medical research and opinion.
37(11):1875-1880
[DOI] 10.1080/03007995.2021.1971181.
[PMID] 34429001.
2021
Trends in Total and Out-of-pocket Payments for Insulin Among Privately Insured U.S. Adults With Diabetes From 2005 to 2018
Diabetes Care.
44(10):e180-e182
[DOI] 10.2337/dc20-2529.
2021
Trends in Total and Out-of-pocket Payments for Noninsulin Glucose-Lowering Drugs Among U.S. Adults With Large-Employer Private Health Insurance From 2005 to 2018
Diabetes Care.
44(4):925-934
[DOI] 10.2337/dc20-2871.
2020
Comment on Segar et al. Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. Diabetes Care 2019;42:2298–2306
Diabetes Care.
43(2):e25-e25
[DOI] 10.2337/dc19-1891.
[PMID] 31959647.
2020
Factors Contributing to the Rising National Cost of Glucose-Lowering Medicines for Diabetes During 2005–2007 and 2015–2017
Diabetes Care.
43(10):2396-2402
[DOI] 10.2337/dc19-2273.
[PMID] 32737138.
2020
Impact of Quality Improvement (QI) Program on 5-Year Risk of Diabetes-Related Complications: A Simulation Study
Diabetes Care.
43(11):2847-2852
[DOI] 10.2337/dc20-0465.
[PMID] 32887705.
2020
Statin Use for Atherosclerotic Cardiovascular Disease Prevention Among Sexual Minority Adults.
Journal of the American Heart Association.
9(24)
[DOI] 10.1161/JAHA.120.018233.
[PMID] 33317368.
2020
Trajectories of Short Physical Performance Battery Are Strongly Associated with Future Major Mobility Disability: Results from the LIFE Study.
Journal of clinical medicine.
9(8)
[DOI] 10.3390/jcm9082332.
[PMID] 32707877.
2020
Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium–Glucose Transporter 2 Inhibitors
Diabetes Care.
43(7):1530-1536
[DOI] 10.2337/dc20-0227.
[PMID] 32345650.
2019
Addressing Regional Differences in Diabetes Progression: Global Calibration for Diabetes Simulation Model.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
22(12):1402-1409
[DOI] 10.1016/j.jval.2019.08.007.
[PMID] 31806197.
2019
Influence of Diabetes Complications on HbA1c Treatment Goals Among Older U.S. Adults: A Cost-effectiveness Analysis
Diabetes Care.
42(11):2136-2142
[DOI] 10.2337/dc19-0381.
Grants
Sep 2022
– Dec 2022
Louisiana Experiment to Address Diabetes: Zero-Dollar Copayment (LEAD-ZDC) for Improving Disease Management
Role: Principal Investigator
Funding: TULANE UNIV.
via CTRS FOR DISEASE CONTROL AND PREVENTION
Sep 2022
– Dec 2022
Assessing Barriers and Facilitators for Participating Structured Lifestyle Intervention and Its Real-world Effectiveness and Cost-effectiveness among US Veterans
Role: Principal Investigator
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION
Sep 2020
ACTIVE
Using Real-world Data to Assess the Burden of Diabetes in Children and Adolescents in Florida
Role: Project Manager
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION
Sep 2020
– Sep 2022
Louisiana Experiment to Address Diabetes: Zero-Dollar Copayment (LEAD-ZDC) for Improving Disease Management
Role: Principal Investigator
Funding: TULANE UNIV.
via CTRS FOR DISEASE CONTROL AND PREVENTION
Jul 2020
– Jul 2021
Simulating Long-Term Outcomes for iGlarlixi using BRAVO Diabetes Model
Role: Principal Investigator
Funding: TULANE UNIV.
via SANOFI
Jun 2020
– Jun 2022
CDC IPA – Assignment Agreement 20IPA2008335DPG
Role: Principal Investigator
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION
Contact Details
Phones:
- Business:
- (352) 294-8323
Emails:
- Business:
- hui.shao@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100496
GAINESVILLE FL 32610 - Business Street:
-
PO Box 100496
GAINESVILLE FL 32610